
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been submitted to the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-3050, an IND-cleared FAP-targeted radiotherapy; and IM-1617, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Immunome is seeking an experienced Principal Data Architect who will define the end-to-end architecture and deployment of the organization’s enterprise data warehouse and analytics platform. This role will be responsible for managing the technical scope, data strategy, data ingestion, delivery roadmap, and partnering with stakeholders on reporting and consumption needs. Phase one will focus on commercial readiness, enabling rapid integration and trusted reporting and operational analytics from key enterprise systems and external data sources. This will be the foundation for a multi-year expansion of enterprise analytics across additional functions.
The Principal Architect will initially be a sole contributor and will lead external consultants and implementation partners while partnering closely with the IT platform team, cybersecurity, technical and business analysts, business leadership, and executives. The role will report to the Senior Director, Business Systems.
Responsibilities
Enterprise & Solution Architecture
Data Warehouse & Analytics Architecture
Master Data Management & Data Governance
AI / Advanced Analytics Enablement
Cross-Domain Collaboration
Qualifications
Knowledge and Skills
Washington State Pay Range $190,132—$223,152 USD
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.